Q3 2015 13F Holders as of 9/30/2015
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
76
-
Total 13F shares, excl. options
-
21.6M
-
Shares change
-
+1.12M
-
Total reported value, excl. options
-
$644M
-
Value change
-
+$32.8M
-
Put/Call ratio
-
0.25
-
Number of buys
-
42
-
Number of sells
-
-37
-
Price
-
$29.76
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q3 2015
98 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2015.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.6M shares
of 105M outstanding shares and own 20.68% of the company stock.
Largest 10 shareholders include Essex Woodlands Health Ventures, Inc. (4.59M shares), FRANKLIN RESOURCES INC (3.24M shares), NQ HCIF GP, Ltd. (3.1M shares), Bank of New York Mellon Corp (1.91M shares), JPMORGAN CHASE & CO (1.39M shares), Polar Capital LLP (1.18M shares), BlackRock Fund Advisors (753K shares), CANADA PENSION PLAN INVESTMENT BOARD (610K shares), Arrowpoint Asset Management, LLC (588K shares), and VANGUARD GROUP INC (483K shares).
This table shows the top 76 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.